CAGRILINTIDE + SEMAGLUTIDE

Weight Loss & MetabolicResearch Only

Exceptionally strong clinical data showing weight losses exceeding 20% in human trials. This combination appears to deliver on the promise of dual-pathway approaches, with results surpassing either component alone.

Clinical researchers focused on combination obesity therapies and pharmaceutical companies developing next-generation weight management drugs.

FDA Status

Research Only

Since Feb 2026

Evidence

Strong

Studies

6 total, 3 human

What is CAGRILINTIDE + SEMAGLUTIDE?

This experimental combination pairs two distinct metabolic regulators to tackle weight management from multiple angles. Researchers are investigating whether combining an amylin analog with a GLP-1 receptor agonist can produce superior results compared to either approach alone. The pairing represents a shift toward multi-target therapeutic strategies in obesity research.

Cagrilintide mimics amylin, a hormone that slows stomach emptying and signals fullness to the brain, while semaglutide activates GLP-1 receptors to regulate blood sugar and suppress appetite. Together, they create overlapping but distinct pathways that reinforce satiety signals and metabolic control. Think of it as hitting the body's weight regulation system from two different angles simultaneously.

What the Research Shows

Solid foundation with 6 human studies including 2 randomized controlled trials showing consistent superiority over both placebo and monotherapy approaches.

Six human studies, including 2 randomized controlled trials, demonstrated that cagrilintide-semaglutide produced weight reductions of 20.4% versus 3.0% with placebo in general populations and 13.7% versus 3.4% with placebo in type 2 diabetes patients, with the combination showing greater efficacy than semaglutide monotherapy (approximately 15% weight loss) and identified as a promising agent in advanced development for weight management across multiple patient populations.